EPS for Abbott Laboratories (ABT) Expected At $0.71

June 21, 2018 - By reb123z

Abbott Laboratories (NYSE:ABT) LogoInvestors sentiment decreased to 0.83 in 2018 Q1. Its down 0.08, from 0.91 in 2017Q4. It fall, as 44 investors sold Abbott Laboratories shares while 606 reduced holdings. 126 funds opened positions while 411 raised stakes. 1.22 billion shares or 0.54% more from 1.22 billion shares in 2017Q4 were reported.
Linscomb And Williams owns 88,970 shares for 0.45% of their portfolio. Clean Yield Grp reported 11,836 shares. Villere St Denis J Co Ltd Liability Corporation invested in 0.84% or 234,765 shares. Vnbtrust Association holds 4,002 shares or 0.14% of its portfolio. 3.10M are owned by Us Bancshares De. Blackrock holds 112.00 million shares. Credit Suisse Ag holds 0.12% of its portfolio in Abbott Laboratories (NYSE:ABT) for 2.07 million shares. Nj State Employees Deferred Compensation Plan reported 14,354 shares. Mckinley Carter Wealth Services holds 0.64% of its portfolio in Abbott Laboratories (NYSE:ABT) for 32,733 shares. Carlson Cap Mngmt reported 59,085 shares. Kazazian Asset Management Ltd Limited Liability Company accumulated 10,688 shares. Capital Planning Advsr Limited Liability invested in 67,822 shares or 1.44% of the stock. Employees Retirement Systems Of Texas holds 414,462 shares. First Midwest National Bank Trust Division accumulated 1.25% or 151,141 shares. Kemper Master Retirement invested 2.25% of its portfolio in Abbott Laboratories (NYSE:ABT).

Since January 30, 2018, it had 1 insider purchase, and 20 sales for $22.32 million activity. Salvadori Daniel Gesua Sive also sold $53,369 worth of Abbott Laboratories (NYSE:ABT) shares. Another trade for 42,665 shares valued at $2.69M was sold by Ford Robert B. 996 Abbott Laboratories (NYSE:ABT) shares with value of $58,635 were sold by Watkin Jared. Another trade for 56,401 shares valued at $3.36 million was made by Fussell Stephen R on Friday, February 16. 1,430 shares were sold by MANNING JOSEPH J, worth $84,344 on Wednesday, February 28. STARKS DANIEL J bought $2.43 million worth of Abbott Laboratories (NYSE:ABT) on Tuesday, February 27.

Analysts expect Abbott Laboratories (NYSE:ABT) to report $0.71 EPS on July, 19.They anticipate $0.09 EPS change or 14.52 % from last quarter’s $0.62 EPS. ABT’s profit would be $1.24 billion giving it 21.88 P/E if the $0.71 EPS is correct. After having $0.59 EPS previously, Abbott Laboratories’s analysts see 20.34 % EPS growth. The stock decreased 0.32% or $0.2 during the last trading session, reaching $62.14. About 5.12 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 41.91% since June 21, 2017 and is uptrending. It has outperformed by 29.34% the S&P500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 14 analysts covering Abbott Laboratories (NYSE:ABT), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. Abbott Laboratories had 19 analyst reports since January 2, 2018 according to SRatingsIntel. Barclays Capital maintained Abbott Laboratories (NYSE:ABT) on Thursday, January 25 with “Overweight” rating. Stifel Nicolaus maintained Abbott Laboratories (NYSE:ABT) rating on Wednesday, January 24. Stifel Nicolaus has “Buy” rating and $71.0 target. As per Wednesday, January 24, the company rating was maintained by BMO Capital Markets. The stock has “Neutral” rating by Citigroup on Tuesday, January 30. The rating was maintained by Jefferies on Wednesday, April 18 with “Buy”. Jefferies maintained the shares of ABT in report on Wednesday, January 24 with “Buy” rating. The rating was maintained by JP Morgan with “Overweight” on Thursday, January 25. The firm earned “Overweight” rating on Tuesday, January 2 by JP Morgan. William Blair upgraded the shares of ABT in report on Thursday, January 25 to “Buy” rating. On Thursday, January 25 the stock rating was maintained by Wells Fargo with “Outperform”.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $108.94 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 232.73 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.